Thin
Commercial active pharmaceutical ingredients and regulatory reference compounds produced under stringent Quality by Design (QbD) parameters.
A deep technical dive into the molecular mechanism, chemical configuration, and structural stability of Szeto-Schiller peptide 31.
SS-31 (D-Arg-2',6'-Dmt-Lys-Phe-NH2) incorporates alternating aromatic and basic amino acids. The strategic placement of 2',6'-dimethyltyrosine (Dmt) alongside D-Arginine confers immense resistance to intracellular aminopeptidases, prolonging half-life in physiological microenvironments.
Unlike conventional antioxidants, SS-31 selectively concentrates at the inner mitochondrial membrane (IMM). Electrostatic and hydrophobic interactions anchor it to cardiolipin, reversing microdomain cristae destabilization and optimizing electron transport chain (ETC) complex flux.
By preventing cardiolipin peroxidative cleavage, SS-31 suppresses mitochondrial permeability transition pore (mPTP) opening and cytochrome c leakage, arresting secondary cellular apoptosis and downstream fibrotic remodeling across ischemic tissues.
| Analytical Parameter | USP/EP Regulatory Specification | Factory In-House Release Capability | Analytical Methodology |
|---|---|---|---|
| Sequence Identification | D-Arg-Dmt-Lys-Phe-NH2 | Confirmed intact mass match (639.8 Da) | ESI-MS / HRMS |
| Chromatographic Purity | ≥ 98.0% (area percentage) | ≥ 99.2% (Batch-consistent) | RP-HPLC (C18 Column, UV 220nm) |
| Impurity Threshold (Single) | ≤ 1.0% | ≤ 0.3% (Individual Unknowns) | High-Performance Gradient HPLC |
| Counter-Ion Salt Exchange | Acetate or Trifluoroacetate (TFA) | Customized Acetate (< 10% w/w) | Ion Chromatography (IC) |
| Bacterial Endotoxin | < 5.0 EU/mg | < 1.0 EU/mg (Ultra-pure formulation) | Limulus Amebocyte Lysate (LAL) |
| Residual Solvents | Complies with ICH Q3C Class 2/3 | Below standard limits (DMF, ACN, DCM) | Headspace GC-MS |
Harnessing the complete chemical synthesis upstream supply network, cutting-edge automated reactor trains, and integrated quality systems.
Our centralized production campus houses multi-ton chemical synthesis suites, delivering sustained industrial capacity for clinical pipelines and commercial supply agreements.
Upstream integration of protected unnatural amino acids (e.g., Fmoc-2',6'-Dmt-OH) mitigates international supply disruptions and eliminates external third-party markups.
Continuous-flow microreactors and eco-friendly cleavage cocktails reduce hazardous reagent volumes, minimizing the environmental footprint and operational overhead.
Comprehensive analytical documentation—including complete impurity profiling, forced degradation studies, and stability packages conforming to ICH Q1A guidelines.
Addressing the shifting paradigm from broad symptomatic remedies to organelle-targeted therapeutics across aging societies.
Acute myocardial infarction and acute kidney injury (AKI) involve acute mitochondrial breakdown. SS-31 preserves microvascular architecture and blunts ischemia-reperfusion injury during invasive interventional procedures.
Retinal ganglion cells and striatal neurons demand immense ATP pools. High-purity SS-31 formulations are actively deployed in clinical models targeting dry AMD, Barth syndrome, and diabetic macular edema.
Global longevity clinics leverage mitochondrial bioenergetics to reverse muscle frailty, insulin desensitization, and systemic immunosenescence driven by chronic inflammatory mitochondrial decay.
Eliminating regulatory frictions, supply chain vulnerabilities, and technical bottlenecks from early drug discovery to commercialization.
Standard synthesis protocols often leave high residual TFA, which is toxic to cell systems. We deliver complete exchange to non-toxic Acetate or Hydrochloride forms with validated assay data.
Temperature-controlled freeze drying guarantees uniform water content (< 5%) and consistent reconstitution clarity, shipped under international cold-chain logistics protocols.
Direct communication channels spanning North America, Europe, Asia, Russia/CIS, and the Middle East, ensuring prompt time-zone aligned quotations and audit-ready packages.
Essential answers regarding synthesis controls, minimum order quantities (MOQ), and global analytical compliance.
Therapeutic peptides, metabolic regulators, and clinical APIs manufactured to rigorous GMP and ISO standards.
